Estrogen replacement therapy for the potential treatment or prevention of alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 223-234

  Miller, Marilyn M ^a   Monjan, Andrew A ^a   Buckholtz, Neil S ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Laboratory of Membrane Biochemistry and Biophysics   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Cognitive function; Epidemiology; Estrogen; Memory

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BRAIN DERIVED GROWTH FACTOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; NERVE GROWTH FACTOR; PHYTOESTROGEN; PROTEIN BCL X; PROTEIN KINASE C; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SYNAPTOPHYSIN;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN BLOOD FLOW; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DISEASE COURSE; ESTROGEN THERAPY; HUMAN; MEMORY; NERVE DEGENERATION; NEUROPROTECTION; PERSONALITY; POSTMENOPAUSE;

EID: 0035680445     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04025.x     Document Type: Conference Paper

References (57)

1. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
2. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature
3. Estrogen therapy in postmenopausal women - Effects on cognitive function and dementia
4. Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960-1974
5. The etiology of Alzheimer's disease: An epidemiologic point of view
6. The prevalence of dementia: A quantitative integration of the literature
7. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings
8. Women, myocardial infarction, and dementia in the very old
9. Alzheimer's disease and other dementing illnesses in a defined United States population: Incidence rates and clinical features
10. Incidence of dementia in the Lundby Study
11. Presenile dementia in Israel
12. Incidence of severe dementia in an urban sample followed from 70 to 79 years of age
13. Hormone replacement therapy and cognition: Systematic review and meta-analysis
14. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives
15. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain
16. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline
17. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex
18. Amyloid beta amyloidosis in Alzheimer's disease
19. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
20. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
21. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides
22. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein
23. Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production
24. Rapid stimulation of amyloid precursor protein release by epidermal growth factor: Role of protein kinase C
25. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein
26. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
27. Fluctuations in relative levels of choline acetyltransferase mRNA in different regions of the rat basal forebrain across the estrous cycle: Effects of estrogen and progesterone
28. Estrogen modulates spontaneous alternation and the cholinergic phenotype in the basal forebrain
29. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease
30. Estrogen, the ovary, and neutotransmitters: Factors associated with aging
31. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain
32. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: Implications for Alzheimer's disease
33. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: Relevance to Alzheimer's disease
34. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition
35. Neuroprotective effects of estradiol in middle-aged female rats
36. Estrogen protects peripheral and cerebral blood vessels from toxicity of Alzheimer peptide amyloid-beta and inflammatory reaction
37. Antiinflammatory effects of estrogen on microglial activation
38. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
39. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
40. Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction
41. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
42. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects
43. Lack of postmenopausal estrogen replacement therapy and the risk of dementia
44. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
45. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
46. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
47. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports
48. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type)
49. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study
50. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
51. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study
52. Theoretical basis for the benefit of postmenopausal estrogen substitution
53. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
54. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study
55. Estrogen as a treatment for Alzheimer disease
56. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia
57. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women